Alpha 认知公司 2025 年季度报告

FORM10-Q (Mark One)☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period endedSeptember 30,2025 or ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period fromto Commission file number:001-42403 Alpha Cognition Inc.(Exact Name of Registrant as Specified in its Charter) (Registrant’s Telephone Number, including Area Code) Securities registered pursuant to Section 12(b) of the Act: None Indicate by checkmark whether the registrant (1)filed all reports required to be filed by Section 13 or 15(d) of the Securities ExchangeAct of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)has been subject to such filing requirements for the past 90 days.Yes☒No☐ Indicate by check mark whether the Registrant has submitted electronically every Interactive Data File required to be submittedpursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that theregistrant was required to submit such files).Yes☒No☐ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smallerreporting company or an emerging growth company. See definitions of “large accelerated filer,” “accelerated filer,” “smaller reportingcompany” and “emerging growth company” in Rule 12b-2 of the Exchange Act: Large Accelerated Filer☐Accelerated Filer☐Non-Accelerated Filer☒Smaller Reporting Company☒Emerging Growth Company☒ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period forcomplying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.☐ Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act): Yes☐No☒ Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practical date:21,742,104common shares, without par value, outstanding as of November 13, 2025. ALPHA COGNITION INC.FORM10-QFor the Quarter Ended September 30, 2025INDEX PagePART I – FINANCIAL INFORMATIONITEM 1. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS1ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OFOPERATIONS20ITEM 3. – QUANTIATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK29ITEM 4. CONTROLS AND PROCEDURES29PART II – OTHER INFORMATIONITEM 1. LEGAL PROCEEDINGS30ITEM 1A. RISK FACTORS30ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS30ITEM 3. DEFAULTS UPON SENIOR SECURITIES30ITEM 4. MINE SAFETY DISCLOSURE31ITEM 5. OTHER INFORMATION31ITEM 6. EXHIBITS31SIGNATURES32 PART I ITEM 1. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS. ALPHA COGNITION INC.CONDENSED CONSOLIDATED BALANCE SHEETS ASSETS Cash and cash equivalents$35,398,899$48,546,210Restricted cash58,40017,872Accounts receivable, net2,845,701-Inventory4,499,363615,133Prepaid expenses and other current assets2,899,2871,071,963Total current assets45,701,65050,251,178Other assets-45,714Equipment, net202,75427,077Intangible assets, net396,809412,969Total assets$46,301,213$50,736,938 NOTE 1 – NATURE OF OPERATIONS Alpha Cognition Inc. (“ACI” or the “Company”) is a commercial stage, biopharmaceutical company dedicated to developingtreatments for patients suffering from neurodegenerative diseases, such as Alzheimer’s Disease and Cognitive Impairment withTraumatic Brain Injury (“TBI”), for which there are limited or no treatment options. The registered and records office of the Companyis 1200 – 750 West Pender Street, Vancouver, BC, V6C 2T8. On July 29, 2024, the Company was granted approval by the U.S. Food and Drug Administration (“FDA”) for the commercializationof ZUNVEYL, previously known as ALPHA-1062, for the treatment of mild-to-moderate Alzheimer’s disease. NOTE 2 – SIGNIFICANT ACCOUNTING POLICIES Basis of Presentation– The accounting and reporting policies of the Company conform to accounting principles generally accepted inthe United States of America and are consistent in all material respects with those applied in our Annual Report on Form 10-K for theyear ended December 31, 2024. The interim condensed consolidated financial statements are unaudited and have been prepared on the same basis as the audited annualfinancial statements and, in management’s opinion, include all adjustments consisting of only normal recurring adjustments necessaryfor the fair statement of the Company’s financial position as of September 30, 2025 and its results of operations and statements ofequity for the three and nine months ended September 30, 2025 and 2024 and cash flows for the nine months ended September 30,2025 and 2024. The results of operations for the three and nine months ended September 30, 2025 are not necessarily indic